This screen revealed that the Src inhibitor, Dasatinib, currently prescribed for the treatment of chronic myeloid leukemia (CML), could trigger rapid de-adhesion of human BRAF V600E mutant melanoma A375 cells from fibronectin-coated glass, as monitored by the enhanced green fluorescent protein (EGFP)-tagged focal adhesion marker paxillin (Figs. 1a, b and Supplementary Movies 1, 2). The gene discussed is BRAF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.